Recent Advances in the Cyclic AMP Signaling Pathway
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2153
Special Issue Editor
Special Issue Information
Dear Colleagues,
The cyclic AMP second messenger is an ancient and universal stress-response signal conserved from bacterium to human. This important molecular switch regulates a myriad of important biological processes under both physiological and pathological conditions. Not surprisingly, current pharmaceutical medications target cyclic nucleotide signaling pathways more than any other pathway.
Intracellular cAMP is generated from ATP by the action of adenylate cyclases (ACs) in response to the activation of guanine-nucleotide-binding proteins (G proteins) prompted by the binding of extracellular ligands to G-protein-coupled receptors (GPCRs). Opposing the action of ACs, cyclic nucleotide phosphodiesterases (PDEs) inactivate cAMP by breaking the phosphodiester bond. In mammals, at least five families of cAMP effector proteins are known: the classic protein kinase A (PKA), the cyclic nucleotide regulated ion channels (CNG and HCN), the exchange proteins directly activated by cAMP (EPAC1 and EPAC2), the Popeye domain containing (POPDC) proteins, and the cyclic nucleotide receptor involved in sperm function (CRIS). These diverse signaling molecules control all facets of cellular function, including but not limited to cell growth, differentiation, secretion, adhesion and motility, gene transcription, protein translation, etc. In this Special Issue, we welcome the submission of high-quality and up-to-date original research or review articles covering the broad field of basic, translational, and clinical research related to the cAMP signaling pathway.
Prof. Dr. Xiaodong Cheng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cAMP
- EPAC
- PKA
- GPCR
- G protein
- adenylate cyclase
- phosphodiesterase (PDE)
- A-kinase anchoring protein (AKAP)
- drug discovery
- signaling cross-talk
